U.S., Sept. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07168434) titled 'Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome' on Aug. 22.
Brief Summary: This is a double-blind, randomized (group assignment by chance), placebo-controlled, multicenter trial which will be conducted over a 13.5-months period The main objective of the research is to demonstrate the efficacy of Saccharomyces boulardii CNCM I-745 on global IBS symptoms, measured by the Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS), in comparison to placebo after 8 weeks.
Secondary efficacy objectives are to evaluate the impact of Saccharomyces boulardii CNCM I-745 on quality of life of IBS patients and on global and ind...